MedTrace Logo

Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias

NCT05286255 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-10-30

No results posted yet for this study

Summary

This is an open-label phase 1 clinical trial of allogeneic umbilical cord derived mesenchymal stromal cells (MSCs) for hospitalized individuals with COVID-19 or other viral pneumonias. Hospitalized individuals who are within 7 days of the onset of a viral pneumonia will be given 2 doses of MSCs at days 1 and 3 after consent. The safety of intravenous infusion will be tested and course of the oxygen response to treatment over 90 days will be evaluated.

Conditions

Interventions

BIOLOGICAL

Allogeneic Mesenchymal Stromal Cells

Intravenous MSCs 1.2-1.5 x 10\^6 cells/kg on Days 1 and 3 after study enrollment

Sponsors & Collaborators

  • Pandorum International, Inc.

    collaborator UNKNOWN

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Charlie Strange, MD · Medical University of South Carolina

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2024-10-01
Completion
2024-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05286255 on ClinicalTrials.gov